Cargando…
Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119519/ https://www.ncbi.nlm.nih.gov/pubmed/37084117 http://dx.doi.org/10.1007/s10096-023-04599-5 |
| _version_ | 1785029037091979264 |
|---|---|
| author | Foo, Hong Phan, Fiona Bagatella, Melissa Petrovski, Irene Nagendra, Vana Acharya, Priya Levy, Miriam Prakoso, Emilia |
| author_facet | Foo, Hong Phan, Fiona Bagatella, Melissa Petrovski, Irene Nagendra, Vana Acharya, Priya Levy, Miriam Prakoso, Emilia |
| author_sort | Foo, Hong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10119519 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101195192023-04-24 Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 Foo, Hong Phan, Fiona Bagatella, Melissa Petrovski, Irene Nagendra, Vana Acharya, Priya Levy, Miriam Prakoso, Emilia Eur J Clin Microbiol Infect Dis Letter to the Editor Springer Berlin Heidelberg 2023-04-21 2023 /pmc/articles/PMC10119519/ /pubmed/37084117 http://dx.doi.org/10.1007/s10096-023-04599-5 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Foo, Hong Phan, Fiona Bagatella, Melissa Petrovski, Irene Nagendra, Vana Acharya, Priya Levy, Miriam Prakoso, Emilia Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title | Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title_full | Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title_fullStr | Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title_full_unstemmed | Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title_short | Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19 |
| title_sort | risk of hepatitis b reactivation following baricitinib or tocilizumab for treatment of covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119519/ https://www.ncbi.nlm.nih.gov/pubmed/37084117 http://dx.doi.org/10.1007/s10096-023-04599-5 |
| work_keys_str_mv | AT foohong riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT phanfiona riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT bagatellamelissa riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT petrovskiirene riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT nagendravana riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT acharyapriya riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT levymiriam riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 AT prakosoemilia riskofhepatitisbreactivationfollowingbaricitinibortocilizumabfortreatmentofcovid19 |